Kasey Dunn
Family · Opelousas, LANPI 1588286389
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $864, 3.0 times the $288 reported in 2021.
Across 143 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$294
- AstraZeneca$282
- Novartis$200
- Pharmacosmos Therapeutics Inc.$191
- Bristol Myers Squibb$179
- Pfizer$165
- plus $2K from 29 others
What the payments were for
- Food & beverage$2,843100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 13 | $294 |
| AstraZeneca(2 entities) | 15 | $282 |
| Novartis | 11 | $200 |
| Pharmacosmos Therapeutics Inc. | 3 | $191 |
| Bristol Myers Squibb | 10 | $179 |
| Pfizer | 10 | $165 |
| Amgen | 10 | $159 |
| Daiichi Sankyo Inc. | 7 | $137 |
| Eisai Inc. | 7 | $133 |
| Sanofi | 6 | $111 |
| Johnson & Johnson | 5 | $93 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| GSK | 5 | $90 |
| Gilead | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $66 |
| Stemline Therapeutics Inc. | 3 | $55 |
| Beigene USA, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Astellas Pharma US Inc | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Karyopharm Therapeutics Inc. | 2 | $35 |
| Blueprint Medicines Corporation | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Boston Scientific | 1 | $26 |
| Beone Medicines USA, Inc. | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Sobi, Inc | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Dova Pharmaceuticals | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$131
How this compares
$2,843 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 87 | $2,129 |
| Letrozole | 176 | $2,065 |
| Ondansetron OdtOndansetron | 45 | $1,722 |
| Anastrozole | 37 | $1,130 |
| Hydroxyurea | 34 | $735 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $653 |
| Alendronate Sodium | 34 | $590 |
| Gabapentin | 41 | $576 |
| Dexamethasone | 26 | $557 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $523 |
| Oxycodone Hcl | 13 | $343 |
| ValacyclovirValacyclovir Hcl | 12 | $322 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $317 |
| Ondansetron Hcl | 17 | $236 |
| Tamoxifen Citrate | 17 | $233 |
Paid to pharmacies, not to this prescriber.
Other family in Opelousas
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.